PTAB Issues Final Written Decisions Finding Claims Of Aflibe

On January 9, 2024, the PTAB issued final written decisions in IPR2022-01225 and IPR2022-01226, filed by Mylan on two Regeneron patents directed to dosing of aflibercept — U.S.

Related Keywords

, Samsung , Mondaq , Ptab Issues Final Written Decisions Finding Claims Of Aflibercept Related Patents Invalid , Intellectual Property , Patent ,